In the past, cancer treatments were mainly given in a hospital or doctor’s office, with health care professionals carefully monitoring the dose and schedule. Now, however, as more and more cancer medicines become available in oral form – pills, tablets, capsules, or drinkable liquids – patients can take many of them independently in the comfort of their own homes.
The key lesson that is emerging is that the mechanism of resistance to immunotherapy will be unique in each patient. The immune response to cancer is shaped by the molecular characteristics of the tumor, the immune profile of the tissue surrounding the tumor (microenvironment), and patient-specific factors, including their genome, and even the composition of microbes in their gut or mouth.
On July 11, JCO Precision Oncology (JCO PO) published an article on ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study, the society’s first-ever clinical trial. The paper discusses the framework of the study and some of the observations to-date.
Four studies from the 2018 ASCO Annual Meeting were featured in a press briefing for reporters on Monday, June 4.
Four Plenary studies from the 2018 ASCO Annual Meeting were featured in a "News of the Day" press briefing on Sunday, June 3, 2018.
Five studies from the 2018 ASCO Annual Meeting were featured in a press briefing for reporters on Saturday, June 2.
Five studies from the 2018 ASCO Annual Meeting were featured in a "News of the Day" press briefing on Friday, June 1, 2018.
Six studies from ASCO's Proceedings I were featured in a virtual presscast for reporters on Wednesday, May 16.
Just a few years ago, the cancer community was elated when the immunotherapy ipililumab became the first treatment to extend life for people with metastatic melanoma. Scientists had found a way to harness a patient’s own immune system to eradicate cancer.